.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

BTK Inhibition for Waldenstrom Macroglobulinemia

EP. 1: The Nature of Waldenstrom Macroglobulinemia

February 15th 2019

EP. 2: Risk Factors in Developing Waldenstrom Macroglobulinemia

February 15th 2019

EP. 3: Waldenstrom Macroglobulinemia: Establishing a Diagnosis

February 15th 2019

EP. 4: Factors Impacting a Diagnosis and Prognosis of WM

February 15th 2019

EP. 5: Waldenstrom Macroglobulinemia: When to Initiate Therapy

February 15th 2019

EP. 6: A Historic Perspective on Frontline WM Management

February 15th 2019

EP. 7: Waldenstrom Macroglobulinemia: Evolving Frontline Treatment

February 15th 2019

EP. 8: Selecting Therapy Through Multiple Lines in WM

February 15th 2019

EP. 9: Targeted Approaches in Waldenstrom Macroglobulinemia

February 15th 2019

EP. 10: BTK Inhibitors in WM: Understanding Safety/Efficacy

February 15th 2019

EP. 11: Future Management of Waldenstrom Macroglobulinemia

February 15th 2019

Latest News

Medicaid Expansion Associated With Improved Breast Cancer Outcomes

Despite Rapid Increase in Immunotherapy Use for Lung Cancer, Survival Benefit for Older Patients Is Modest

I’m No Longer Stubborn When It Comes to Cancer Screenings

Teaching Children — and the World — to Use Breathing Techniques for Cancer-Related Pain

View More Latest News